Wuxi Vision raises $13M to commercialize cataract devices

Flag of China
WuXi Vision estimates there are 130 million potential cataract patients aged 60 years and older in China. (daderot / Wikimedia Commons)

Wuxi Vision Pro has raised $13 million to advance its intraocular lens business. The Chinese medical device company picked up a local approval for its products last year, setting it up to service the country’s growing number of cataract patients.

Working out of a development and manufacturing facility in California, Wuxi Vision has established a portfolio of intraocular lenses designed to improve the vision of patients following cataract surgery. The products picked up CE mark designations in Europe before going on to be registered by the China Food and Drug Administration in July.

The regulatory progress has opened up commercial opportunities to Wuxi Vision, dialling up its need for money. Qiming Venture Partners and Ruijian Capital have stepped in with a $13 million series B round.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

Nisa Leung, managing partner of Qiming, made the investment after concluding Wuxi Vision has the products and capabilities to make a mark in China and beyond. 

“With Leiming aspheric [intraocular lenses] successfully passing clinical trials and being put into the market, I am very optimistic about the future of the company and have committed to investing in the outstanding enterprise,” Leung said in a statement. “I hope that Leiming will become a leading brand in China and will expand to international markets.”

China alone represents a big opportunity. Wuxi Vision estimates there are 130 million potential cataract patients aged 60 years and older in the country and expects almost 5 million patients a year to undergo surgery by 2020.

Suggested Articles

Boston Scientific’s deep brain stimulation implant for treating Parkinson’s disease has been approved by the FDA as safe to use within an MRI.

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.

Alcon has announced plans to launch its daily disposable contact lens in the U.S. made from a new material.